THOUSAND OAKS, Calif., February 24, 2026
Amgen announced it will present at the 46th Annual TD Cowen Health Care Conference on March 2, 2026, at 1:10 p.m. ET, highlighting updates on its business strategy, commercial portfolio and pipeline progress. Senior executives Kave Niksefat, Senior Vice President of Global Marketing and Access, and Justin Claeys, Senior Vice President of Finance, will represent the company during the investor-focused session. The presentation will be webcast live and archived for replay, providing investors and stakeholders access to management insights into Amgen’s biotechnology pipeline, financial outlook and innovation strategy.
Investor Engagement and Business Strategy Focus
The TD Cowen Health Care Conference is a prominent annual gathering of biotechnology, pharmaceutical and healthcare leaders, providing a platform for corporate updates and strategic outlook discussions. Amgen’s participation reflects its ongoing commitment to transparency with investors and the broader life sciences community. During the session, company leadership is expected to discuss pipeline advancements, commercialization strategy, global market access initiatives and financial performance, offering insight into how Amgen is positioning itself within a competitive and rapidly evolving biotech landscape.
As one of the largest biotechnology companies globally, Amgen continues to focus on strengthening its diversified portfolio across oncology, cardiovascular disease, inflammatory disorders, rare diseases and metabolic conditions. Investor conferences such as TD Cowen allow the company to communicate progress in late-stage clinical programs, regulatory milestones and long-term growth priorities while reinforcing its capital allocation strategy.
Biotechnology Innovation and Pipeline Expansion
Advertisement
Founded more than 45 years ago, Amgen has played a foundational role in shaping the modern biotechnology industry. Headquartered in Thousand Oaks, California, the company leverages advanced biologics research, genetic data analytics and precision medicine approaches to develop innovative therapies targeting complex diseases. Its pipeline includes investigational biologics and novel therapeutic modalities designed to address unmet medical needs in cancer, cardiology, immunology and obesity-related conditions.
Amgen’s research and development engine continues to focus on integrating human genetics, advanced manufacturing technologies and biologic drug platforms to accelerate the discovery and delivery of next-generation treatments. The company’s broad clinical portfolio spans multiple late-stage programs and recently approved therapies, positioning it as a leader in both established and emerging therapeutic areas. Participation in major healthcare conferences provides a venue to outline progress in ongoing Phase II and Phase III trials, highlight commercialization efforts, and reaffirm long-term R&D investments.
Corporate Leadership and Market Positioning
Amgen remains a significant force within global capital markets and the biotechnology sector. It is one of the 30 companies included in the Dow Jones Industrial Average® and is also part of the Nasdaq-100 Index®. Recognition from industry and business publications for innovation and workplace culture underscores its sustained leadership position. By engaging with institutional investors and analysts at major healthcare conferences, Amgen aims to reinforce confidence in its growth trajectory, pipeline sustainability and operational excellence.
The live webcast of the presentation will be accessible through the company’s Investor Relations platform, with replay availability for at least 90 days following the event. This investor communication initiative supports Amgen’s broader objective of maintaining consistent dialogue with stakeholders while advancing its mission to discover, develop, manufacture and deliver transformative medicines.
Source: Amgen press release
